- $8.12bn
- $7.95bn
- $2.43bn
- 94
- 25
- 95
- 83
Annual cashflow statement for Chemed, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 319 | 269 | 250 | 273 | 302 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 29.8 | 22.3 | 38 | 43.4 | 46.7 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 45.7 | -25.5 | -33.5 | -38.5 | 9.91 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Taxes Payable | |||||
| Change in Other Liabilities | |||||
| Net Change in Other Assets & Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | 489 | 309 | 310 | 330 | 417 |
| Capital Expenditures | -58.8 | -58.7 | -57.3 | -56.9 | -49.5 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -2.73 | 0.918 | -2.08 | -3.79 | -94.4 |
| Acquisition of Business | |||||
| Sale of Fixed Assets | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -61.6 | -57.8 | -59.4 | -60.6 | -144 |
| Financing Cash Flow Items | -25.1 | -15.3 | -18.3 | -9.07 | -11.5 |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -271 | -381 | -209 | -79.8 | -359 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 157 | -130 | 41.2 | 190 | -85.6 |